Array BioPharma Advances ARRY-797 to Phase II

Array BioPharma has started dosing ARRY-797, a small molecule p38 inhibitor, in a Phase II trial to evaluate the drug for treating pain in dental patients undergoing third molar extraction.

The randomized, double-blind, placebo-controlled, parallel-group trial will assess the safety, tolerability and analgesic efficacy of ARRY-797 dosed either after the operation or both before and after surgery.

The trial will enroll 150 patients and be conducted at two centers in the U.S., Array said.